Cargando…

Cracking KRAS(G12C) across all solid tumors: the new kid on the block for tissue-agnostic precision medicine

Detalles Bibliográficos
Autores principales:	Bhamidipati, D., Subbiah, V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336412/ https://www.ncbi.nlm.nih.gov/pubmed/37393631 http://dx.doi.org/10.1016/j.esmoop.2023.101591

Ejemplares similares

KRAS G12C mutation: from undruggable target to potentially agnostic biomarker
por: El Osta, Badi
Publicado: (2023)

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Precision medicine becomes reality—tumor type-agnostic therapy
por: Yan, Li, et al.
Publicado: (2018)

Nanotherapeutics for solid organ transplantation: new kid on the block
por: Xu, Gang, et al.
Publicado: (2023)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

MapperPlus: Agnostic clustering of high-dimension data for precision medicine
por: Datta, Esha, et al.
Publicado: (2023)

KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
por: Garcia-Robledo, Juan Esteban, et al.
Publicado: (2022)

Precision Oncology Comes of Age: Tumor-Agnostic Approaches
por: Lewis, Colleen, et al.
Publicado: (2020)

New kid on the block
Publicado: (2008)

New Kid on the Block
por: Reinheckel, Thomas
Publicado: (2017)

SUT-Crack: A comprehensive dataset for pavement crack detection across all methods
por: Sabouri, Mohammadreza, et al.
Publicado: (2023)

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
por: Hofmann, Marco H., et al.
Publicado: (2022)

Echinacea no cure-all for kids.
por: Washam, Cynthia
Publicado: (2004)

The Bacillus Agnostic
Publicado: (1911)

Developing Drugs for Tissue‐Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine
por: Seligson, Nathan D., et al.
Publicado: (2020)

Commentary: AADI: New kid on the block
por: Pathak-Ray, Vanita
Publicado: (2018)

NAADP Signaling: New Kids on the Block
por: Guse, Andreas H.
Publicado: (2022)

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

The New Kid on the Block: Mass Photometry
por: Graciani, Guillaume, et al.
Publicado: (2023)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors
por: Pavone, Giuliana, et al.
Publicado: (2021)

Agnostic Tendency in Doctors
Publicado: (1885)

NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies
por: Marchetti, Antonio, et al.
Publicado: (2022)

Targeting KRAS(G12V) mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
por: Ai, Qi, et al.
Publicado: (2023)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations
por: Pantsar, Tatu
Publicado: (2020)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Precise and efficient silencing of mutant Kras(G12D) by CRISPR-CasRx controls pancreatic cancer progression
por: Jiang, Wang, et al.
Publicado: (2020)

GPR40 Modulators: New Kid on the Block
por: Basu, Ananda, et al.
Publicado: (2013)

Integrative weaning index: New kid on the block!
por: Govil, Deepak, et al.
Publicado: (2015)

The cool new kid on the block: Lung cryobiopsy
por: Esmail, A, et al.
Publicado: (2023)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation
por: Wang, Judy, et al.
Publicado: (2022)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
por: Hagenbeek, Thijs J., et al.
Publicado: (2023)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5ndn75vd62a9lssqncpl5hi6a6